ClinicalTrials.gg
CompletedNCT01486927Updated Aug 9, 2016Results posted

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

A Phase 2/3 interventional study of rVIII-SingleChain and Octocog alfa in Hemophilia A, sponsored by CSL Behring. Completed at 56 sites in 20 countries. Open to male participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-08-09.

Sponsored by CSL Behring (part of CSL Limited) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
175
Allocation
Not applicable
Ages
12 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing F8 protein, human in Hemophilia A — none open to participants now, none under way, none of them phase 3. F8 protein, human · Hemophilia A.

Enrollment
Largest of 18
175 · median 44
Started
2012
with 1 other
Phase 2/3
4 of 18
none open now
Registered
13th of 18
by date
Lead sponsor
1 of 18
CSL Behring

Among the 18 studies testing F8 protein, human in Hemophilia A, this one has the largest enrollment, is one of 2 that started in 2012, is one of 4 in phase 2/3, and was the 13th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

None of the 18 studies testing F8 protein, human in Hemophilia A is open now. The open studies under Hemophilia A, anywhere →

About F8 protein, human

F8 protein, human: first FDA approval 1974 (Koate, Koate-Dvi), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing F8 protein, human in Hemophilia A as a file.
02

Study summary

This is an open-label, non-randomized, efficacy, safety and pharmacokinetic (PK) study comparing octocog alfa and rVIII-SingleChain. The study consists of three parts, a PK period (Part 1), a continuation of dosing safety and efficacy period (Part 2) and a safety, efficacy, and repeat PK period (Part 3) and also includes a surgical sub-study for subjects enrolled in Parts 2 and 3.

03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of severe hemophilia A defined as \<1% FVIII:C documented in medical records.
  • Males between 18 and 65 years of age (Parts 1 and 2).
  • Males between 12 and 65 years of age (Part 3).
  • Subjects who have received or are currently receiving FVIII products (plasma-derived and/or recombinant FVIII) and have had >150 exposure days (EDs) with a FVIII product
  • Written for study participation obtained before undergoing any study specific procedures.

Exclusion criteria

Exclusion Criteria:

  • Any history of or current FVIII inhibitors
  • Any first order family history of FVIII inhibitors
  • Use of an Medicinal Product within 30 days prior to the first rVIII-SingleChain administration.
  • Administration of any cryoprecipitate, whole blood or plasma within 30 days prior to administration of rVIII-SingleChain or reference product.
  • Known (allergic reaction or anaphylaxis) to any FVIII product or hamster protein.
  • Any known congenital or acquired coagulation disorder other than congenital FVIII deficiency.
  • count \< 100,000/µL at screening.
  • (HIV) positive subjects with a \< 200/mm3, in their medical history or at screening if available results are older than one year. (HIV positive subjects may participate in the study and antiviral therapy are permitted, at the discretion of the Investigator).
  • Subject currently receiving IV immunomodulating agents such as immunoglobulin or chronic systemic treatment.
  • Subject with serum (AST) or serum alanine aminotransferase (ALT) values > 5 times (x) the (ULN) at Screening.
  • Subjects with serum creatinine values > 2 x ULN at Screening.
  • Evidence of thrombosis, including deep vein thrombosis, stroke, pulmonary embolism, myocardial infarction and arterial embolus within 3 months prior to Day 1.
  • Experienced life-threatening bleeding episode or had major surgery or an orthopedic surgical procedure during the 3 months prior to Day 1.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Recombinant Factor VIII (rFVIII)

    Biological: rVIII-SingleChain · Biological: Octocog alfa

Interventions

  • In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg recombinant, single-chain coagulation factor VIII (rVIII-SingleChain) preceded by a 4-day washout period. In Parts 2 and 3 of the study, subjects received repeat injections of rVIII-SingleChain either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor. Subjects participating in the Part 3 PK analyses received a single infusion of 50 IU/kg rVIII-SingleChain and a repeat dose of the same strength of rVIII-SingleChain after 3 to 6 months. Subjects from Parts 2 and 3 participating in the surgical substudy received an individualized dose regimen of rVIII-SingleChain, based on the type of surgery and the clinical status of the subject.

    Also known as: Recombinant Factor VIII (rFVIII), CSL627

  • BiologicalOctocog alfa

    In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg of octocog alfa preceded by a 4-day washout period. Octocog alfa is the international nonproprietary name (INN) for recombinant human coagulation factor VIII.

    Also known as: Human coagulation factor VIII (rDNA)

06

What researchers measure

Primary outcomes

  1. Treatment Success

    The investigator rated the efficacy of the treatment based on a 4-point rating scale "excellent, good, moderate or poor/no response". Efficacy ratings of "excellent" or "good" were considered treatment success for this end point; the percentage of bleeding events with a rating of excellent or good and the 95% confidence interval are presented. The denominator includes all treated bleeding events. The 95% confidence interval is based on a model to account for within-subject correlation.

    Time frame: Up to 24 months

  2. Inhibitor Formation to FVIII

    Number of subjects who develop inhibitors to FVIII

    Time frame: Up to 24 months

  3. Annualized Spontaneous Bleeding Rate

    The annualized spontaneous bleeding rate (AsBR) was derived for each subject as follows: 365.25\*(number of spontaneous bleeding episodes requiring treatment) / (observed treatment period of interest).

    Time frame: Up to 24 months

  4. Treatment Success During the Peri-operative Surgical Sub-study

    Subjects received rVIII-SingleChain before and during surgery based on the type of surgery and the clinical status of the subject. The investigator rated the efficacy of the treatment based on a 4-point surgical treatment rating scale of "excellent, good, moderate or poor/no response". Efficacy ratings of "excellent" or "good" were considered treatment success for this end point. The rate of success, defined as the percentage of surgeries with a rating of excellent or good for hemostatic efficacy on the surgical treatment scale is presented for the Surgical Population, based on the total number of surgeries (N=16) as denominator.

    Time frame: From the start of surgery through the post-operative recovery (generally up to 14 days after surgery)

Secondary outcomes

  1. AUC0-∞ (Part 1)

    AUC0-∞ (AUC from 0 extrapolated to infinity) of a single infusion of octocog alfa and rVIII-SingleChain without correction for subject's predose plasma FVIII activity. FVIII activity values for octocog alfa are dose-adjusted for chromogenic potency.

    Time frame: Before infusion and at up to 10 time points within 72 hours of infusion

  2. Cmax (Part 1)

    Cmax of a single infusion of octocog alfa and rVIII-SingleChain with correction for subject's predose plasma FVIII activity. FVIII activity values for octocog alfa are dose-adjusted for chromogenic potency.

    Time frame: Before infusion and at up to 10 time points within 72 hours of infusion

  3. Tmax (Part 1)

    Tmax = time of Cmax (with correction for subject's predose plasma FVIII activity) after a single infusion of octocog alfa and rVIII-SingleChain.

    Time frame: Before infusion and at up to 10 time points within 72 hours of infusion

  4. Half-life (t1/2) (Part 1)

    Half-life (t1/2) of a single infusion of octocog alfa and rVIII-SingleChain without correction for subject's predose plasma FVIII activity.

    Time frame: Before infusion and at up to 10 time points within 72 hours of infusion.

  5. Mean Residence Time (MRT) (Part 1)

    Mean residence time (MRT) of a single infusion of octocog alfa and rVIII-SingleChain without correction for subject's predose plasma FVIII activity.

    Time frame: Before infusion and at up to 10 time points within 72 hours of infusion

  6. Clearance (Cl) (Part 1)

    Clearance (Cl) of a single infusion of octocog alfa and rVIII-SingleChain without correction for subject's predose plasma FVIII activity. FVIII activity values for octocog alfa are dose-adjusted for chromogenic potency.

    Time frame: Before infusion and at up to 10 time points within 72 hours of infusion

  7. Volume of Distribution at Steady-state (Vss) (Part 1)

    Volume of distribution at steady-state (Vss) of a single infusion of octocog alfa and rVIII-SingleChain without correction for subject's predose plasma FVIII activity. FVIII activity values for octocog alfa are dose-adjusted for chromogenic potency.

    Time frame: Before infusion and at up to 10 time points within 72 hours of infusion

  8. Incremental Recovery (Part 1)

    Incremental recovery of a single infusion of octocog alfa and rVIII-SingleChain with correction for subject's predose plasma FVIII activity. FVIII activity values for octocog alfa are dose-adjusted for chromogenic potency.

    Time frame: At 30 minutes after infusion

  9. Annualized Bleeding Rate for Total Bleeds and Traumatic Bleeds

    The annualized bleeding rate was derived for each subject as follows: 365.25\*(number of bleeding episodes requiring treatment) / (observed treatment period of interest).

    Time frame: Up to 24 months

  10. Proportion of Bleeding Episodes Requiring 1, 2, 3 or > 3 Infusions of rVIII-SingleChain to Achieve Hemostasis

    Percentage of bleeding episodes requiring 1, 2, 3 or \> 3 infusions of rVIII-SingleChain to achieve hemostasis. The denominator includes all treated bleeding episodes.

    Time frame: During the study (up to 24 months; assessed at Months 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 21 and 24)

Other outcomes

  1. Incremental Recovery (Part 3)

    Incremental recovery of an initial and repeat infusion of rVIII-SingleChain with correction for subject's predose plasma FVIII activity.

    Time frame: At 30 minutes after infusion

  2. Volume of Distribution at Steady-state (Vss) (Part 3)

    Volume of distribution at steady-state (Vss) of an initial and repeat infusion of rVIII-SingleChain without correction for subject's predose plasma FVIII activity.

    Time frame: Before infusion and at up to 12 time points within 96 hours of infusion.

  3. Clearance (Cl) (Part 3)

    Clearance (Cl) of an initial and repeat infusion of rVIII-SingleChain without correction for subject's predose plasma FVIII activity.

    Time frame: Before infusion and at up to 12 time points within 96 hours of infusion.

  4. Mean Residence Time (MRT) (Part 3)

    Mean residence time (MRT) of an initial and repeat infusion of rVIII-SingleChain without correction for subject's predose plasma FVIII activity.

    Time frame: Before infusion and at up to 12 time points within 96 hours of infusion.

  5. Half-life (t1/2) (Part 3)

    Half-life (t1/2) of an initial and repeat infusion of rVIII-SingleChain without correction for subject's predose plasma FVIII activity.

    Time frame: Before infusion and at up to 12 time points within 96 hours of infusion.

  6. Tmax (Part 3)

    Tmax = time of Cmax (with correction for subject's predose plasma FVIII activity) after an initial and repeat infusion of rVIII-SingleChain.

    Time frame: Before infusion and at up to 12 time points within 96 hours of infusion.

  7. Cmax (Part 3)

    Cmax of an initial and repeat infusion of rVIII-SingleChain with correction for subject's predose plasma FVIII activity.

    Time frame: Before infusion and at up to 12 time points within 96 hours of infusion

  8. AUC0-∞ (Part 3)

    AUC0-∞ (AUC from 0 extrapolated to infinity) of an initial and repeat infusion of rVIII-SingleChain without correction for subject's predose plasma FVIII activity.

    Time frame: Before infusion and at up to 12 time points within 96 hours of infusion

07

Results

Posted Aug 9, 2016

Participant flow

This multicenter, multinational study enrolled subjects at 54 participating study centers in the United States, Japan, Europe, Australia, Canada, Lebanon, Malaysia, Philippines, Russian Federation, South Africa, and Ukraine.

Participant flow — Overall Study
MilestoneRecombinant Factor VIII (rFVIII)
Started174
Completed161
Not completed13
Withdrew: Knee surgery (prior to surgery substudy)1
Withdrew: Physician decision1
Withdrew: 50 exposure days not reached2
Withdrew: Withdrawal by subject8
Withdrew: Subject did not reach 6 mo of treatment1

Outcome measures

PrimaryTreatment Success

The investigator rated the efficacy of the treatment based on a 4-point rating scale "excellent, good, moderate or poor/no response". Efficacy ratings of "excellent" or "good" were considered treatment success for this end point; the percentage of bleeding events with a rating of excellent or good and the 95% confidence interval are presented. The denominator includes all treated bleeding events. The 95% confidence interval is based on a model to account for within-subject correlation.

Time frame:
Up to 24 months
Reported as:
Number · % bleeding events successfully treated
Treatment Success
% bleeding events successfully treatedrVIII-SingleChain On-demandrVIII-SingleChain ProphylaxisrVIII-SingleChain
Treatment Success92.4 (87.8 to 95.3)92.2 (86.3 to 95.8)92.3 (88.9 to 94.8)
PrimaryInhibitor Formation to FVIII

Number of subjects who develop inhibitors to FVIII

Time frame:
Up to 24 months
Reported as:
Number · participants
Inhibitor Formation to FVIII
participantsRecombinant Factor VIII (rFVIII)
Inhibitor Formation to FVIII0
PrimaryAnnualized Spontaneous Bleeding Rate

The annualized spontaneous bleeding rate (AsBR) was derived for each subject as follows: 365.25\*(number of spontaneous bleeding episodes requiring treatment) / (observed treatment period of interest).

Time frame:
Up to 24 months
Reported as:
Median · Number of spontaneous bleeds per year
Annualized Spontaneous Bleeding Rate
Number of spontaneous bleeds per yearrVIII-SingleChain On-demandrVIII-SingleChain Prophylaxis
Annualized Spontaneous Bleeding Rate11.73 (2.8 to 36.5)0.00 (0.0 to 2.4)
Statistical analysis
  • rVIII-SingleChain On-demand vs rVIII-SingleChain Prophylaxis · Poisson, regression · p = < 0.0001 · Rate ratio: 0.08 · 95% CI 0.07 to 0.10
PrimaryTreatment Success During the Peri-operative Surgical Sub-study

Subjects received rVIII-SingleChain before and during surgery based on the type of surgery and the clinical status of the subject. The investigator rated the efficacy of the treatment based on a 4-point surgical treatment rating scale of "excellent, good, moderate or poor/no response". Efficacy ratings of "excellent" or "good" were considered treatment success for this end point. The rate of success, defined as the percentage of surgeries with a rating of excellent or good for hemostatic efficacy on the surgical treatment scale is presented for the Surgical Population, based on the total number of surgeries (N=16) as denominator.

Time frame:
From the start of surgery through the post-operative recovery (generally up to 14 days after surgery)
Reported as:
Number · % of surgeries with successful treatment
Treatment Success During the Peri-operative Surgical Sub-study
% of surgeries with successful treatmentrVIII-SingleChain Surgical
Treatment Success During the Peri-operative Surgical Sub-study100
SecondaryAUC0-∞ (Part 1)

AUC0-∞ (AUC from 0 extrapolated to infinity) of a single infusion of octocog alfa and rVIII-SingleChain without correction for subject's predose plasma FVIII activity. FVIII activity values for octocog alfa are dose-adjusted for chromogenic potency.

Time frame:
Before infusion and at up to 10 time points within 72 hours of infusion
Reported as:
Mean · IU*h/dL
AUC0-∞ (Part 1)
IU*h/dLPK Population (Part 1)
Octocog alfa1550 ± 552
rVIII-SingleChain2090 ± 650
SecondaryCmax (Part 1)

Cmax of a single infusion of octocog alfa and rVIII-SingleChain with correction for subject's predose plasma FVIII activity. FVIII activity values for octocog alfa are dose-adjusted for chromogenic potency.

Time frame:
Before infusion and at up to 10 time points within 72 hours of infusion
Reported as:
Mean · IU/dL
Cmax (Part 1)
IU/dLPK Population (Part 1)
Octocog alfa116 ± 18.1
rVIII-SingleChain113 ± 17.4
SecondaryTmax (Part 1)

Tmax = time of Cmax (with correction for subject's predose plasma FVIII activity) after a single infusion of octocog alfa and rVIII-SingleChain.

Time frame:
Before infusion and at up to 10 time points within 72 hours of infusion
Reported as:
Median · hours
Tmax (Part 1)
hoursPK Population (Part 1)
Octocog alfa0.583 (0.450 to 0.800)
rVIII-SingleChain0.683 (0.467 to 1.25)
SecondaryHalf-life (t1/2) (Part 1)

Half-life (t1/2) of a single infusion of octocog alfa and rVIII-SingleChain without correction for subject's predose plasma FVIII activity.

Time frame:
Before infusion and at up to 10 time points within 72 hours of infusion.
Reported as:
Mean · hours
Half-life (t1/2) (Part 1)
hoursPK Population (Part 1)
Octocog alfa13.3 ± 4.36
rVIII-SingleChain14.5 ± 3.77
SecondaryMean Residence Time (MRT) (Part 1)

Mean residence time (MRT) of a single infusion of octocog alfa and rVIII-SingleChain without correction for subject's predose plasma FVIII activity.

Time frame:
Before infusion and at up to 10 time points within 72 hours of infusion
Reported as:
Mean · hours
Mean Residence Time (MRT) (Part 1)
hoursPK Population (Part 1)
Octocog alfa17.1 ± 5.57
rVIII-SingleChain20.4 ± 5.49
SecondaryClearance (Cl) (Part 1)

Clearance (Cl) of a single infusion of octocog alfa and rVIII-SingleChain without correction for subject's predose plasma FVIII activity. FVIII activity values for octocog alfa are dose-adjusted for chromogenic potency.

Time frame:
Before infusion and at up to 10 time points within 72 hours of infusion
Reported as:
Mean · mL/h/kg
Clearance (Cl) (Part 1)
mL/h/kgPK Population (Part 1)
Octocog alfa3.68 ± 1.41
rVIII-SingleChain2.64 ± 0.846
SecondaryVolume of Distribution at Steady-state (Vss) (Part 1)

Volume of distribution at steady-state (Vss) of a single infusion of octocog alfa and rVIII-SingleChain without correction for subject's predose plasma FVIII activity. FVIII activity values for octocog alfa are dose-adjusted for chromogenic potency.

Time frame:
Before infusion and at up to 10 time points within 72 hours of infusion
Reported as:
Mean · mL/kg
Volume of Distribution at Steady-state (Vss) (Part 1)
mL/kgPK Population (Part 1)
Octocog alfa57.1 ± 11.3
rVIII-SingleChain50.0 ± 7.51
SecondaryIncremental Recovery (Part 1)

Incremental recovery of a single infusion of octocog alfa and rVIII-SingleChain with correction for subject's predose plasma FVIII activity. FVIII activity values for octocog alfa are dose-adjusted for chromogenic potency.

Time frame:
At 30 minutes after infusion
Reported as:
Mean · [IU/dL]/[IU/kg]
Incremental Recovery (Part 1)
[IU/dL]/[IU/kg]PK Population (Part 1)
Octocog alfa2.32 ± 0.381
rVIII-SingleChain2.24 ± 0.357
SecondaryAnnualized Bleeding Rate for Total Bleeds and Traumatic Bleeds

The annualized bleeding rate was derived for each subject as follows: 365.25\*(number of bleeding episodes requiring treatment) / (observed treatment period of interest).

Time frame:
Up to 24 months
Reported as:
Median · Number of bleeds per year
Annualized Bleeding Rate for Total Bleeds and Traumatic Bleeds
Number of bleeds per yearrVIII-SingleChain On-demandrVIII-SingleChain Prophylaxis
Total Bleeds19.64 (6.2 to 46.5)1.14 (0.0 to 4.2)
Traumatic Bleeds3.12 (0.0 to 8.4)0.00 (0.0 to 0.9)
SecondaryProportion of Bleeding Episodes Requiring 1, 2, 3 or > 3 Infusions of rVIII-SingleChain to Achieve Hemostasis

Percentage of bleeding episodes requiring 1, 2, 3 or \> 3 infusions of rVIII-SingleChain to achieve hemostasis. The denominator includes all treated bleeding episodes.

Time frame:
During the study (up to 24 months; assessed at Months 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 21 and 24)
Reported as:
Number · Percentage of bleeding episodes
Proportion of Bleeding Episodes Requiring 1, 2, 3 or > 3 Infusions of rVIII-SingleChain to Achieve Hemostasis
Percentage of bleeding episodesrVIII-SingleChain On-demandrVIII-SingleChain ProphylaxisrVIII-SingleChain
Requiring 1 infusion for hemostasis82.776.780.9
Requiring 2 infusions for hemostasis12.014.012.6
Requiring 3 infusions for hemostasis3.223.883.42
Requiring >3 infusions for hemostasis2.035.433.07
Other pre-specifiedIncremental Recovery (Part 3)

Incremental recovery of an initial and repeat infusion of rVIII-SingleChain with correction for subject's predose plasma FVIII activity.

Time frame:
At 30 minutes after infusion
Reported as:
Mean · [IU/dL]/[IU/kg]
Incremental Recovery (Part 3)
[IU/dL]/[IU/kg]rVIII-SingleChain PK Population (Part 3)
Initial, n = 631.85 ± 0.404
Repeat, n = 291.99 ± 0.352
Other pre-specifiedVolume of Distribution at Steady-state (Vss) (Part 3)

Volume of distribution at steady-state (Vss) of an initial and repeat infusion of rVIII-SingleChain without correction for subject's predose plasma FVIII activity.

Time frame:
Before infusion and at up to 12 time points within 96 hours of infusion.
Reported as:
Mean · mL/kg
Volume of Distribution at Steady-state (Vss) (Part 3)
mL/kgrVIII-SingleChain PK Population (Part 3)
Initial, n = 6459.5 ± 14.2
Repeat, n = 3053.1 ± 8.74
Other pre-specifiedClearance (Cl) (Part 3)

Clearance (Cl) of an initial and repeat infusion of rVIII-SingleChain without correction for subject's predose plasma FVIII activity.

Time frame:
Before infusion and at up to 12 time points within 96 hours of infusion.
Reported as:
Mean · mL/h/kg
Clearance (Cl) (Part 3)
mL/h/kgrVIII-SingleChain PK Population (Part 3)
Initial, n = 643.15 ± 1.21
Repeat, n = 303.05 ± 1.1
Other pre-specifiedMean Residence Time (MRT) (Part 3)

Mean residence time (MRT) of an initial and repeat infusion of rVIII-SingleChain without correction for subject's predose plasma FVIII activity.

Time frame:
Before infusion and at up to 12 time points within 96 hours of infusion.
Reported as:
Mean · hours
Mean Residence Time (MRT) (Part 3)
hoursrVIII-SingleChain PK Population (Part 3)
Initial, n = 6420.3 ± 5.36
Repeat, n = 3018.9 ± 5.39
Other pre-specifiedHalf-life (t1/2) (Part 3)

Half-life (t1/2) of an initial and repeat infusion of rVIII-SingleChain without correction for subject's predose plasma FVIII activity.

Time frame:
Before infusion and at up to 12 time points within 96 hours of infusion.
Reported as:
Mean · hours
Half-life (t1/2) (Part 3)
hoursrVIII-SingleChain PK Population (Part 3)
Initial, n = 6414.1 ± 3.82
Repeat, n = 3012.9 ± 3.7
Other pre-specifiedTmax (Part 3)

Tmax = time of Cmax (with correction for subject's predose plasma FVIII activity) after an initial and repeat infusion of rVIII-SingleChain.

Time frame:
Before infusion and at up to 12 time points within 96 hours of infusion.
Reported as:
Median · hours
Tmax (Part 3)
hoursrVIII-SingleChain PK Population (Part 3)
Initial, n = 630.333 (0.117 to 1.22)
Repeat, n = 290.317 (0.117 to 0.667)
Other pre-specifiedCmax (Part 3)

Cmax of an initial and repeat infusion of rVIII-SingleChain with correction for subject's predose plasma FVIII activity.

Time frame:
Before infusion and at up to 12 time points within 96 hours of infusion
Reported as:
Mean · IU/dL
Cmax (Part 3)
IU/dLrVIII-SingleChain PK Population (Part 3)
Initial, n = 6399.9 ± 19.9
Repeat, n = 29108 ± 18.5
Other pre-specifiedAUC0-∞ (Part 3)

AUC0-∞ (AUC from 0 extrapolated to infinity) of an initial and repeat infusion of rVIII-SingleChain without correction for subject's predose plasma FVIII activity.

Time frame:
Before infusion and at up to 12 time points within 96 hours of infusion
Reported as:
Mean · IU*h/dL
AUC0-∞ (Part 3)
IU*h/dLrVIII-SingleChain PK Population (Part 3)
Initial, n = 641830 ± 640
Repeat, n = 301880 ± 649

Adverse events

Collected over For the duration of the study, approximately 2 years, 10 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Population—8/174 (4.6%)45/174 (25.9%)
Most frequent serious events
Most frequent serious events
EventSafety Population
Ankle fractureInjury, poisoning and procedural complications1/174
Blood uric acid increasedInvestigations1/174
Tonsillar haemorrhageRespiratory, thoracic and mediastinal disorders1/174
HypersensitivityImmune system disorders1/174
AnaemiaBlood and lymphatic system disorders1/174
ThrombocytopeniaBlood and lymphatic system disorders1/174
Suicidal ideationPsychiatric disorders1/174
Varices oesophagealGastrointestinal disorders1/174
Postoperative wound infectionInfections and infestations1/174
Viral infectionInfections and infestations1/174
Most frequent other events
Most frequent other events
EventSafety Population
ArthralgiaMusculoskeletal and connective tissue disorders20/174
NasopharyngitisInfections and infestations18/174
HeadacheNervous system disorders13/174

Baseline characteristics

Age, Continuous
Age, Continuous(years)Recombinant Factor VIII (rFVIII)
Mean31.3 ± 11.77
Age, Customized
Age, Customized(participants)Recombinant Factor VIII (rFVIII)
Adolescents (12-17 years)14
Adults (18-65 years)160
Sex: Female, Male
Sex: Female, Male(Participants)Recombinant Factor VIII (rFVIII)
Female0
Male174
Type of FVIII product used before enrollment
Type of FVIII product used before enrollment(participants)Recombinant Factor VIII (rFVIII)
Plasma-derived Product83
Recombinant Product91
Treatment modality of FVIII therapy before enrollment
Treatment modality of FVIII therapy before enrollment(participants)Recombinant Factor VIII (rFVIII)
Prophylaxis82
On-demand92
08

Study locations

56 sites
  • Study Site
    Sacramento, California 95817, United States
  • Study Site
    San Diego, California 92103, United States
  • Study Site
    Aurora, Colorado 80045, United States
  • Study Site
    Hartford, Connecticut 06106, United States
  • Study Site
    Miami, Florida 33136, United States
  • Study Site
    Chicago, Illinois 60612-3833, United States
  • Study Site
    New Orleans, Louisiana 70112, United States
  • Study Site
    Houston, Texas 77030, United States
  • Study Site
    Milwaukee, Wisconsin 53226, United States
  • Study Site
    Nedlands, WA 6009, Australia
  • Study Site
    Perth, WA 6000, Australia
  • Study Site
    Graz, 8036, Austria
  • Study Site
    Vienna, 1090, Austria
  • Study Site
    New Brunswick, E2L 4L2, Canada
  • Study Site
    Hradec Králové, 500 05, Czech Republic
  • Study Site
    Berlin, 10249, Germany
  • Study Site
    Berlin, 13353, Germany
  • Study Site
    Bonn, 53127, Germany
  • Study Site
    Gießen, 35392, Germany
  • Study Site
    Hamburg, 20095, Germany
  • Study Site
    Hannover, 30159, Germany
  • Study Site
    Heidelberg, 69123, Germany
  • Study Site
    Debrecen, H-4032, Hungary
  • Study Site
    Florence, 50134, Italy
  • Study Site
    Milan, 20122, Italy
  • Study Site
    Padova, 35123, Italy
  • Study Site
    Padova, 35128, Italy
  • Study Site
    Torino, 10126, Italy
  • Study Site
    Kashihara, Nara, Japan
  • Study Site
    Kitakyushu, Fukuoka, Japan
  • Study Site
    Nagoya, 466-85660, Japan
  • Study Site
    Nishinomiya, Hyogo, Japan
  • Study Site
    Okayama, 710-8602, Japan
  • Study Site
    Saitama, Japan
  • Study Site
    Suginami-ku, Tokyo, Japan
  • Study Site
    Tokyo, 160-0023, Japan
  • Study Site
    Beirut, Lebanon
  • Study Site
    Kuala Lumpur, 50400, Malaysia
  • Study Site
    Utrecht, 3584 CX, Netherlands
  • Study Site
    Cebu City, 6000, Philippines
  • Study Site
    Davao City, 8000, Philippines
  • Study Site
    Wroclaw, Silesia 50-367, Poland
  • Study Site
    Gdansk, 80-952, Poland
  • Study Site
    Krakow, 31-501, Poland
  • Study Site
    Bucharest, 011026, Romania
  • Study Site
    Barnaul, 656038, Russian Federation
  • Study Site
    Kemerovo, 650066, Russian Federation
  • Study Site
    Cape Town, 7295, South Africa
  • Study Site
    Johannesburg, 2193, South Africa
  • Study Site
    Barcelona, Spain
  • Study Site
    La Coruna, Spain
  • Study Site
    Valencia, 46026, Spain
  • Study Site
    Dnipropetrovsk, 49102, Ukraine
  • Study Site
    Donetsk, 830045, Ukraine
  • Study Site
    Lviv, 79044, Ukraine
  • Study Site
    London, NW3 2QG, United Kingdom
09

References and documents

Publications

  • Mahlangu J, Kuliczkowski K, Karim FA, Stasyshyn O, Kosinova MV, Lepatan LM, Skotnicki A, Boggio LN, Klamroth R, Oldenburg J, Hellmann A, Santagostino E, Baker RI, Fischer K, Gill JC, P'Ng S, Chowdary P, Escobar MA, Khayat CD, Rusen L, Bensen-Kennedy D, Blackman N, Limsakun T, Veldman A, St Ledger K, Pabinger I; AFFINITY Investigators. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood. 2016 Aug 4;128(5):630-7. doi: 10.1182/blood-2016-01-687434. Epub 2016 Jun 21. PubMed 27330001 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 1 year 8 months after primary completion. A results delay was requested in Dec 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2011
First posted
Dec 7, 2011
Start
Feb 2012
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results delay requested
Dec 11, 2015
Results first posted
Aug 9, 2016
Last update
Aug 9, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01486927
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Dec 7, 2011
Start date
Feb 2012
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Aug 9, 2016
Last update
Aug 9, 2016

Study contacts

Program Director
study director · CSL Behring
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lonoctocog alfa · F8 protein, human

Start the discussion